Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing

BACKGROUND: Epidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF are mutated in several types of cancer, affecting the clinical response to EGFR inhibitors. Mutations in the EGFR kinase domain predict sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Borràs, Emma, Jurado, Ismael, Hernan, Imma, Gamundi, María José, Dias, Miguel, Martí, Isabel, Mañé, Begoña, Arcusa, Àngels, Agúndez, José AG, Blanca, Miguel, Carballo, Miguel
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2011
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3192787/
https://ncbi.nlm.nih.gov/pubmed/21943394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-406
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items